| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results |
| 24 Sep 2026 |
8-K: Regulation FD Disclosure
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology |
| 27 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel |
| 09 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
As previously disclosed, on October 31, 2025, Kyverna Therapeutics, Inc. (the “Company”) entered into that certain Loan and Security Agreement (the “Loan and Security Agreement”) with Oxford Finance LLC, as collateral agent (the “Collate... |
| 02 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 27, 2026, Kyverna Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 60,530,293 shares of the Company’s common stock outstanding as of March 30, 2026, the record date for... |
| 18 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Kyverna Therapeutics, Inc. (the “Company”) is pleased to offer you employment beginning on May 18, 2026 (the “Start Date”); provided, however, if your employment does not commence on the Start Date, this letter shall be null and void and... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated |
| 04 May 2026 |
8-K: Other Events
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer |
| 22 Apr 2026 |
8-K: Regulation FD Disclosure
Exhibit 99.1 Highlighting New Data from Our Neuroimmunology Franchise at AAN April 22, 2026 ©2026 Kyverna Therapeutics, Inc. |
| 22 Apr 2026 |
8-K: Regulation FD Disclosure
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting |
| 20 Apr 2026 |
8-K: Regulation FD Disclosure
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks |
| 26 Mar 2026 |
8-K: Results of Operations and Financial Condition
Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 |
| 24 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization |
| 03 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
1. Purposes of the Plan. The purposes of the Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Com... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Kyverna Therapeutics, Inc. (the “Company”) is pleased to offer you employment beginning on January 12, 2026 (the “Start Date”); provided, however, if your employment does not commence on the Start Date, this letter shall be null and void... |
| 18 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Kyverna Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives... |
| 15 Dec 2025 |
8-K: Regulation FD Disclosure
Exhibit 99.1 Topline Data: KYSA-8 Registrational Trial of Miv-cel (KYV-101) in Stiff Person Syndrome (SPS) December 15, 2025 ©2025 Kyverna Therapeutics, Inc. |
| 15 Dec 2025 |
8-K: Regulation FD Disclosure
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026 |
Loading...